William R. Sellers

85.3k total citations · 19 hit papers
165 papers, 34.8k citations indexed

About

William R. Sellers is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William R. Sellers has authored 165 papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Molecular Biology, 54 papers in Oncology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William R. Sellers's work include PI3K/AKT/mTOR signaling in cancer (29 papers), Cancer-related Molecular Pathways (29 papers) and Cancer Genomics and Diagnostics (16 papers). William R. Sellers is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (29 papers), Cancer-related Molecular Pathways (29 papers) and Cancer Genomics and Diagnostics (16 papers). William R. Sellers collaborates with scholars based in United States, Switzerland and Germany. William R. Sellers's co-authors include Matthew Meyerson, Francisca Vázquez, Heidi Greulich, William G. Kaelin, Pasi A. Jänne, Massimo Loda, J. Guillermo Paez, Frederic J. Kaye, Jeffrey C. Lee and Noriaki Nakamura and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

William R. Sellers

157 papers receiving 34.0k citations

Hit Papers

EGFR Mutations in Lung Ca... 1992 2026 2003 2014 2004 2002 2005 2004 2005 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
    2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. profile →
  2. Gene expression correlates of clinical prostate cancer behavior
    2002 1.8k citations Phillip G. Febbo, Massimo Loda et al. profile →
  3. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    2005 1.1k citations Levi A. Garraway, Hans R. Widlund et al. profile →
  4. Molecular characterization of the tumor microenvironment in breast cancer
    2004 1.0k citations Rameen Beroukhim, Dale Porter et al. profile →
  5. BRAF mutation predicts sensitivity to MEK inhibition
    2005 1.0k citations David B. Solit, Levi A. Garraway et al. profile →
  6. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    2008 954 citations Sauveur-Michel Maira, Frédéric Stauffer et al. Molecular Cancer Therapeutics profile →
  7. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
    2004 781 citations Pradip K. Majumder, Phillip G. Febbo et al. profile →
  8. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties
    1992 777 citations William G. Kaelin, William R. Sellers et al. profile →
  9. The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
    2004 725 citations William R. Sellers et al. profile →
  10. Phosphorylation of the PTEN Tail Regulates Protein Stability and Function
    2000 662 citations Francisca Vázquez, William R. Sellers et al. profile →
  11. Quantitative Proteomics of the Cancer Cell Line Encyclopedia
    2020 574 citations Judit Jané‐Valbuena, Dale Porter et al. profile →
  12. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
    2013 539 citations William R. Sellers, Nancy Pryer et al. profile →
  13. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
    2005 536 citations Heidi Greulich, Whei Feng et al. profile →
  14. Interaction between the retinoblastoma protein and the oncoprotein MDM2
    1995 512 citations William R. Sellers et al. profile →
  15. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
    1999 500 citations Massimo Loda, William R. Sellers et al. profile →
  16. TSC2 regulates VEGF through mTOR-dependent and -independent pathways
    2003 429 citations Francisca Vázquez, William R. Sellers et al. profile →
  17. An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
    2013 425 citations David A. Ruddy, John E. Monahan et al. Cancer Discovery profile →
  18. Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors
    1996 323 citations William R. Sellers, William G. Kaelin et al. profile →
  19. Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
    2009 310 citations Rameen Beroukhim, Arianna Di Napoli et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William R. Sellers United States 82 22.7k 13.6k 10.5k 7.1k 2.9k 165 34.8k
Carlos L. Arteaga United States 101 19.8k 0.9× 18.4k 1.3× 7.2k 0.7× 6.4k 0.9× 2.9k 1.0× 432 34.7k
William L. Gerald United States 93 18.9k 0.8× 12.0k 0.9× 12.1k 1.2× 8.8k 1.2× 2.9k 1.0× 241 36.1k
Erik Larsson Sweden 56 21.9k 1.0× 8.3k 0.6× 6.9k 0.7× 9.7k 1.4× 2.2k 0.8× 208 34.1k
Neal Rosen United States 100 24.7k 1.1× 12.2k 0.9× 5.7k 0.5× 4.2k 0.6× 1.6k 0.6× 255 34.8k
Massimo Loda United States 98 23.0k 1.0× 12.4k 0.9× 9.8k 0.9× 10.8k 1.5× 2.9k 1.0× 469 40.1k
Ming‐Sound Tsao Canada 98 16.5k 0.7× 15.3k 1.1× 13.8k 1.3× 8.3k 1.2× 1.7k 0.6× 653 37.2k
Bülent Arman Aksoy United States 24 17.3k 0.8× 8.0k 0.6× 6.6k 0.6× 8.5k 1.2× 1.6k 0.5× 46 25.7k
Paul S. Meltzer United States 93 22.7k 1.0× 9.2k 0.7× 5.6k 0.5× 7.2k 1.0× 5.3k 1.8× 384 36.0k
Ethan Cerami United States 15 17.3k 0.8× 7.7k 0.6× 6.5k 0.6× 8.1k 1.1× 1.5k 0.5× 34 25.6k
Jianjiong Gao United States 29 17.6k 0.8× 7.7k 0.6× 6.5k 0.6× 8.1k 1.2× 1.5k 0.5× 58 26.1k

Countries citing papers authored by William R. Sellers

Since Specialization
Citations

This map shows the geographic impact of William R. Sellers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William R. Sellers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William R. Sellers more than expected).

Fields of papers citing papers by William R. Sellers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William R. Sellers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William R. Sellers. The network helps show where William R. Sellers may publish in the future.

Co-authorship network of co-authors of William R. Sellers

This figure shows the co-authorship network connecting the top 25 collaborators of William R. Sellers. A scholar is included among the top collaborators of William R. Sellers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William R. Sellers. William R. Sellers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jin, Cyrus Y., Moritz Hunkeler, Kathleen M. Mulvaney, William R. Sellers, & Eric S. Fischer. (2025). Substrate adaptors are flexible tethering modules that enhance substrate methylation by the arginine methyltransferase PRMT5. Journal of Biological Chemistry. 301(2). 108165–108165.
2.
Shirole, Nitin H., Yenarae Lee, Amy Goodale, et al.. (2025). Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. Cancer Discovery. 15(7). 1484–1504. 2 indexed citations
3.
Wu, Xuewei, Xiaobao Yang, Yan Xiong, et al.. (2021). Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer. 2(4). 429–443. 47 indexed citations
4.
Horn, Thomas, Stéphane Ferretti, Nicolas Ebel, et al.. (2016). High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Research. 76(23). 6950–6963. 24 indexed citations
5.
Menezes, Daniel L., Pietro Taverna, Michael Rugaard Jensen, et al.. (2012). The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo. Molecular Cancer Therapeutics. 11(3). 730–739. 57 indexed citations
6.
Tiedt, Ralph, Pascal Furet, B.A. Appleton, et al.. (2011). A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. Cancer Research. 71(15). 5255–5264. 99 indexed citations
7.
Halilovic, Ensar, Qing‐Bai She, Qing Ye, et al.. (2010). PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Research. 70(17). 6804–6814. 133 indexed citations
8.
Jané‐Valbuena, Judit, Hans R. Widlund, Sven Perner, et al.. (2010). An Oncogenic Role for ETV1 in Melanoma. Cancer Research. 70(5). 2075–2084. 81 indexed citations
9.
Beroukhim, Rameen, Arianna Di Napoli, Kirsten D. Mertz, et al.. (2009). Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. Cancer Research. 69(11). 4674–4681. 310 indexed citations breakdown →
10.
Wee, Susan, Zainab Jagani, Kay X. Xiang, et al.. (2009). PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Research. 69(10). 4286–4293. 354 indexed citations
11.
Engelsen, Ingeborg B., Ingunn M. Stefansson, Rameen Beroukhim, et al.. (2008). HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 32(2). 307–16. 27 indexed citations
12.
Maira, Sauveur-Michel, Frédéric Stauffer, Josef Brueggen, et al.. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics. 7(7). 1851–1863. 954 indexed citations breakdown →
13.
Lin, William M., Alissa C. Baker, Rameen Beroukhim, et al.. (2008). Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma. Cancer Research. 68(3). 664–673. 215 indexed citations
14.
Gaither, Alex, Dale Porter, Yao Yao, et al.. (2007). A Smac Mimetic Rescue Screen Reveals Roles for Inhibitor of Apoptosis Proteins in Tumor Necrosis Factor-α Signaling. Cancer Research. 67(24). 11493–11498. 178 indexed citations
15.
Perner, Sven, Francesca Demichelis, Rameen Beroukhim, et al.. (2006). TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research. 66(17). 8337–8341. 388 indexed citations
16.
Vázquez, Francisca, Satomi Matsuoka, William R. Sellers, et al.. (2006). Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proceedings of the National Academy of Sciences. 103(10). 3633–3638. 155 indexed citations
17.
Signoretti, Sabina, Maira M. Pires, James W. Horner, et al.. (2005). p63 regulates commitment to the prostate cell lineage. Proceedings of the National Academy of Sciences. 102(32). 11355–11360. 121 indexed citations
18.
Zhao, Xiaojun, Barbara A. Weir, Thomas LaFramboise, et al.. (2005). Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. Cancer Research. 65(13). 5561–5570. 242 indexed citations
19.
Zhao, Xiaojun, Cheng Li, J. Guillermo Paez, et al.. (2004). An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays. Cancer Research. 64(9). 3060–3071. 401 indexed citations
20.
Berger, Raanan, Phillip G. Febbo, Pradip K. Majumder, et al.. (2004). Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells. Cancer Research. 64(24). 8867–8875. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlos L. Arteaga Breakdown of academic impact, for papers by William L. Gerald Breakdown of academic impact, for papers by Erik Larsson Breakdown of academic impact, for papers by Neal Rosen Breakdown of academic impact, for papers by Massimo Loda Breakdown of academic impact, for papers by Ming‐Sound Tsao Breakdown of academic impact, for papers by Bülent Arman Aksoy Breakdown of academic impact, for papers by Paul S. Meltzer Breakdown of academic impact, for papers by Ethan Cerami Breakdown of academic impact, for papers by Jianjiong Gao
Rankless by CCL
2026